These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28002704)

  • 41. Prescription drug monitoring programs and buprenorphine maintenance: clinical considerations.
    Hoefer M; Petrakis I
    Am J Addict; 2014; 23(6):616-7. PubMed ID: 25251308
    [No Abstract]   [Full Text] [Related]  

  • 42. [Use of buprenorphine as a substitute treatment for opiate dependence in the Toxicology Clinics--introductory clinical report].
    Radomska M; Pach J; Chrostek Maj J
    Przegl Lek; 2001; 58(4):351-3. PubMed ID: 11450367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Opioid dependence: New national guidelines must allow maintenance treatment].
    Heilig M
    Lakartidningen; 2013 Oct 23-29; 110(43-44):1908-9. PubMed ID: 24340431
    [No Abstract]   [Full Text] [Related]  

  • 44. Detoxification and treating opioid dependence.
    Contreras JA
    JAMA; 2006 Feb; 295(8):886-7; author reply 887-8. PubMed ID: 16493097
    [No Abstract]   [Full Text] [Related]  

  • 45. Buprenorphine in primary care: perspectives on clinical and research priorities.
    Rottnek F; Scherrer JF
    Fam Pract; 2019 Nov; 36(6):677-679. PubMed ID: 31536619
    [No Abstract]   [Full Text] [Related]  

  • 46. New pharmacological tool approved for opioid addiction.
    Sansovich D
    HIV Clin; 2004; 16(3):9-11. PubMed ID: 15366107
    [No Abstract]   [Full Text] [Related]  

  • 47. As Overdoses Climb, Emergency Departments Begin Treating Opioid Use Disorder.
    Rubin R
    JAMA; 2018 Jun; 319(21):2158-2160. PubMed ID: 29800009
    [No Abstract]   [Full Text] [Related]  

  • 48. In-office opiate treatment "not a panacea": physicians slow to embrace therapeutic option.
    Vastag B
    JAMA; 2003 Aug; 290(6):731-5. PubMed ID: 12915410
    [No Abstract]   [Full Text] [Related]  

  • 49. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.
    Arfken CL; Johanson CE; di Menza S; Schuster CR
    J Subst Abuse Treat; 2010 Sep; 39(2):96-104. PubMed ID: 20598829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.
    Sigmon SC; C Meyer A; Hruska B; Ochalek T; Rose G; Badger GJ; Brooklyn JR; Heil SH; Higgins ST; Moore BA; Schwartz RP
    Addict Behav; 2015 Dec; 51():136-42. PubMed ID: 26256469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Good Place to Start - Low-Threshold Buprenorphine Initiation.
    Berk J
    N Engl J Med; 2020 Aug; 383(8):701-703. PubMed ID: 32813944
    [No Abstract]   [Full Text] [Related]  

  • 52. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
    Stock C; Shum JH
    J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unusual presentations for pharmacotherapy-poppy seed dependence.
    Lloyd-Jones DM; Bonomo Y
    Drug Alcohol Rev; 2006 Jul; 25(4):375-6. PubMed ID: 16854666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Buprenorphine diversion and misuse in outpatient practice.
    Lofwall MR; Martin J; Tierney M; Fatséas M; Auriacombe M; Lintzeris N
    J Addict Med; 2014; 8(5):327-32. PubMed ID: 25221985
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The untapped potential of office-based buprenorphine treatment.
    Sigmon SC
    JAMA Psychiatry; 2015 Apr; 72(4):395-6. PubMed ID: 25671806
    [No Abstract]   [Full Text] [Related]  

  • 56. Buprenorphine: "field trials" of a new drug.
    Agar M; Bourgois P; French J; Murdoch O
    Qual Health Res; 2001 Jan; 11(1):69-84. PubMed ID: 11147165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors.
    Knudsen HK; Ducharme LJ; Roman PM; Link T
    J Subst Abuse Treat; 2005 Sep; 29(2):95-106. PubMed ID: 16135338
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Time Is Now: The Role of Pharmacotherapies in Expanding Treatment for Opioid Use Disorder.
    Gordon AJ; Jenkins JA
    Subst Abus; 2015; 36(2):127-8. PubMed ID: 25826044
    [No Abstract]   [Full Text] [Related]  

  • 59. Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine.
    Mendelson J; Flower K; Pletcher MJ; Galloway GP
    Exp Clin Psychopharmacol; 2008 Oct; 16(5):435-41. PubMed ID: 18837640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Buprenorphine Prescribing: To Expand or Not to Expand.
    Li X; Shorter D; Kosten TR
    J Psychiatr Pract; 2016 May; 22(3):183-92. PubMed ID: 27123798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.